Article
Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
Breast cancer research and treatment - 1 Dec 2012
Gökmen-Polar Yesim, Liu Yi, Toroni Rachel A, Sanders Kerry L, Mehta Rutika, Badve Sunil, Rommel Christian, Sledge George W
Abstract excerpt
Aberrant activation of the mammalian target of rapamycin (mTOR) signaling plays an important role in breast cancer progression and represents a potential therapeutic target for breast cancer. In this study, we report the impact of the investigational drug MLN0128, a potent and selective small molecule active-site TORC1/2 kinase inhibitor, on tumor growth and metastasis using human breast cancer xenograft models....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.